NTHI: Child shows early improvement after compassionate-use intranasal NEO100; NeOnc names Abu Dhabi banking exec to board

AI Summary

NeOnc reported a critically ill three-year-old with an aggressive brain tumor treated under compassionate-use intranasal NEO100 is breathing without ventilator support and beginning to move his legs. The company notes this single uncontrolled case was administered outside its pediatric trial and frames the update alongside regulatory and corporate milestones — a 24‑patient Phase 2a topline for NEO100 (6‑month PFS 48.9%, median OS 26.09 months), Abu Dhabi IND pathway progress and a new board appointment — plus a $15M registered direct raise and an upcoming Nov. 17 FDA End-of-Phase‑1 meeting for NEO212.

Positives

Compassionate-use child reportedly off ventilator and showing regained leg movement after intranasal NEO100
Clinical/regulatory traction: Phase 2a topline (n=24) with 6‑month PFS 48.9% and median OS 26.09 months; FDA Rare Pediatric Disease designation and Abu Dhabi IND pathway
Completed $15M registered direct offering and added Ali Alabedin (First Abu Dhabi Bank) to the board, strengthening Abu Dhabi/institutional ties

Negatives

Single compassionate-use case is uncontrolled and cannot establish that NEO100 caused the improvement
Existing efficacy data are small and preliminary (Phase 2a n=24); pediatric use reported outside an active trial
Article is a paid editorial disclosure, indicating potential promotional bias